International business development expert joins Dicot Pharma
Uppsala, Sweden, November 19, 2024. The potency drug developer Dicot Pharma, which recently initiated a phase 2a clinical trial and was listed on Nasdaq First North, is intensifying its focus on future commercialization. One measure is strengthening the management team with the appointment of a Chief Business Officer.
The international business development expert Håkan Wickholm has been recruited for the CBO role. He brings extensive global experience from business development and multi-commercial roles within AstraZeneca such as Regional Business Development Director for Europe, the Middle East, and Africa, Nordic Vice President of Mature Brands and Local Products and CEO in the Gulf States. Håkan has also held several CEO and CBO positions in smaller development companies, including Lytix Biopharma.
“It is gratifying to announce this addition, which reflects our strong focus on business development and future commercialization. Håkan's many years of experience from the global arena, particularly at a major company like AstraZeneca, align perfectly with our progressive strategy," says Dicot Pharma CEO Elin Trampe.
"I’m genuinely excited to contribute to Dicot Pharma’s commercialization efforts. I hope to leverage my experience from both large and small pharmaceutical companies, as well as the unique industry conditions of various regions, to shape a robust strategy that will bring LIB-01 all the way to market,” comments Håkan Wickholm.
For further information, please contact:
Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: [email protected]
About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma's strategy is to develop LIB-01 under own auspices until phase 2a study and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.
Dicot Pharma is listed on Nasdaq First North and has approximately 7,600 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.
This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.